HUP0402307A2 - Kisméretű szerves molekulák a sejtproliferáció szabályozásához és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents
Kisméretű szerves molekulák a sejtproliferáció szabályozásához és ezeket tartalmazó gyógyszerkészítmények és alkalmazásukInfo
- Publication number
- HUP0402307A2 HUP0402307A2 HU0402307A HUP0402307A HUP0402307A2 HU P0402307 A2 HUP0402307 A2 HU P0402307A2 HU 0402307 A HU0402307 A HU 0402307A HU P0402307 A HUP0402307 A HU P0402307A HU P0402307 A2 HUP0402307 A2 HU P0402307A2
- Authority
- HU
- Hungary
- Prior art keywords
- thien
- group
- aryl
- value
- heterocyclyl
- Prior art date
Links
- 230000004663 cell proliferation Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 3-chlorobenzo[b]thien-2-yl Chemical group 0.000 abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 abstract 8
- 125000003118 aryl group Chemical group 0.000 abstract 7
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract 3
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Pregnancy & Childbirth (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
A találmány (IX) általános képletű vegyületekre, ahol Ar aril- vagyheteroarilgyűrű; X jelentése -C(=O)-, -C(=S)-, -S(O2)-, -S(O)- vagymetiléncsoport; Y hiányzik; Z hiányzik vagy aril-, karbociklil-,heterociklil- vagy heteroarilgyűrű, vagy alkil-, nitro-, cianocsoportvagy halogénatom; M metiléncsoport, vagy két M együtt etén- vagyetincsoport; Cy aril-, heterociklil-, heteroaril- vagycikloalkilcsoport; Cy' 3-klórbenzo[b]tien-2-il-, 3-fluorbenzo[b]tien-2-il- vagy 3-metilbenzo[b]tien-2-ilcsoport, ahol a benzolgyűrűhelyettesített; i értéke 0, kivéve az N-Ml-Y-Ar szekvenciát, ahol iértéke 1; és k értéke 0; (X) általános képletű vegyületekre, ahol Araril- vagy heteroarilgyűrű; X jelentése -C(=O)-, -C(=S)-, -S(O2)-, -S(O)- vagy metiléncsoport; Y hiányzik; Z hiányzik vagy aril-,karbociklil-, heterociklil- vagy heteroarilgyűrű, vagy alkil-, nitro-vagy cianocsoport vagy halogénatom; R hidrogénatom vagy alkilcsoport;Cy' 3-klórbenzo[b]tien-2-il-, 3-fluorbenzo[b]tien-2-il- vagy 3-metilbenzo[b]tien-2-ilcsoport, ahol a benzolgyűrű helyettesített; Mmetiléncsoport, vagy két M együtt etén- vagy etincsoportot jelent,ahol az Mj-ben néhány vagy az összes M egy gyűrűs szerkezetet vagyszerkezetrészt alkot; j értéke 2, 3, 4, 5, 6 vagy 7; i értéke 0,kivéve az N-Mi-Y-Ar szekvenciát, ahol i értéke 1; és k értéke 0;valamint (XI) általános képletű vegyületekre, ahol Ar aril- vagyheteroarilgyűrű; X jelentése -C(=O)-, -C(=S)-, -S(O2)-, -S(O)- vagymetiléncsoport; Y hiányzik; Z hiányzik, vagy aril-, karbociklil-,heterociklil- vagy heteroarilgyűrűt, vagy alkil-, nitro- vagycianocsoportot vagy halogénatomot jelent; R hidrogénatom vagyalkilcsoport; Cy' 3-klórbenzo[b]tien-2-il-, 3-fluorbenzo[b]tien-2-il-vagy 3-metilbenzo[b]tien-2-ilcsoport, ahol a benzolgyűrűhelyettesített; M metiléncsoport, vagy két M együtt etén- vagyetincsoportot jelent; Cy aril-, heterociklil-, heteroaril- vagycikloalkilcsoport; i értéke 0, kivéve az N-Mi-Y-Ar szekvenciát, ahol iértéke 1; és k értéke 0, és az ezeket a vegyületeket tartalmazógyógyászati készítményekre vonatkozik. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/964,276 US6683192B2 (en) | 2000-03-30 | 2001-09-26 | Small organic molecule regulators of cell proliferation |
PCT/US2002/029522 WO2003027234A2 (en) | 2001-09-26 | 2002-09-18 | Small organic molecule regulators of cell proliferation |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP0402307A2 true HUP0402307A2 (hu) | 2005-02-28 |
Family
ID=25508346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0402307A HUP0402307A2 (hu) | 2001-09-26 | 2002-09-18 | Kisméretű szerves molekulák a sejtproliferáció szabályozásához és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
Country Status (19)
Country | Link |
---|---|
US (1) | US6683192B2 (hu) |
EP (1) | EP1436287A4 (hu) |
JP (1) | JP4563028B2 (hu) |
KR (2) | KR101051535B1 (hu) |
CN (1) | CN1578779B (hu) |
AU (1) | AU2002336580B2 (hu) |
BR (1) | BR0212825A (hu) |
CA (1) | CA2461709A1 (hu) |
EA (1) | EA200400355A1 (hu) |
GE (1) | GEP20063855B (hu) |
HU (1) | HUP0402307A2 (hu) |
IL (3) | IL161104A0 (hu) |
MX (1) | MXPA04002880A (hu) |
NO (1) | NO20041260L (hu) |
NZ (1) | NZ531970A (hu) |
PL (1) | PL371343A1 (hu) |
UA (1) | UA78225C2 (hu) |
WO (1) | WO2003027234A2 (hu) |
ZA (1) | ZA200402322B (hu) |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7230000B1 (en) | 1999-10-27 | 2007-06-12 | Cytokinetics, Incorporated | Methods and compositions utilizing quinazolinones |
US7671200B2 (en) | 1999-10-27 | 2010-03-02 | Cytokinetics, Inc. | Quinazolinone KSP inhibitors |
US6683108B1 (en) * | 2000-03-30 | 2004-01-27 | Curis, Inc. | Agonists of hedgehog signaling pathways and uses related thereto |
US7354932B2 (en) * | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
MXPA04006136A (es) * | 2001-12-21 | 2004-11-01 | Anormed Inc | Compuestos heterociclicos que se unen a receptor de quimiocina con eficacia incrementada. |
US6924376B2 (en) | 2002-04-17 | 2005-08-02 | Cytokinetics, Inc. | Compounds, compositions and methods |
CA2485148A1 (en) | 2002-05-09 | 2003-11-20 | Cytokinetics, Inc. | Pyrimidinone compounds, compositions and methods |
US7361368B2 (en) | 2002-06-28 | 2008-04-22 | Advanced Cardiovascular Systems, Inc. | Device and method for combining a treatment agent and a gel |
US7632679B2 (en) * | 2002-07-16 | 2009-12-15 | The Trustees Of Columbia University In The City Of New York | Systems and methods for screening for modulators of neural differentiation |
US7390659B2 (en) | 2002-07-16 | 2008-06-24 | The Trustees Of Columbia University In The City Of New York | Methods for inducing differentiation of embryonic stem cells and uses thereof |
US20040224302A1 (en) * | 2002-07-16 | 2004-11-11 | Thomas Jessel | Systems and methods for screening for modulators of neural differentiation |
FR2842422B1 (fr) * | 2002-07-16 | 2006-06-30 | Univ Aix Marseille Ii | Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations |
US6949538B2 (en) | 2002-07-17 | 2005-09-27 | Cytokinetics, Inc. | Compounds, compositions, and methods |
US8383158B2 (en) * | 2003-04-15 | 2013-02-26 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
CA2547338A1 (en) * | 2003-12-19 | 2005-07-07 | Curis, Inc. | Composition and methods for modulating cns activity |
PL1789390T3 (pl) | 2004-09-02 | 2012-04-30 | Genentech Inc | Pirydylowe inhibitory szlaku sygnałowego hedgehog |
US20070281040A1 (en) * | 2004-09-30 | 2007-12-06 | The University Of Chicago | Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents |
US20060165739A1 (en) * | 2005-01-06 | 2006-07-27 | Mary Kay Inc. | Alcohol-free microemulsion composition |
US9539410B2 (en) | 2005-04-19 | 2017-01-10 | Abbott Cardiovascular Systems Inc. | Methods and compositions for treating post-cardial infarction damage |
US20080125745A1 (en) | 2005-04-19 | 2008-05-29 | Shubhayu Basu | Methods and compositions for treating post-cardial infarction damage |
US8828433B2 (en) | 2005-04-19 | 2014-09-09 | Advanced Cardiovascular Systems, Inc. | Hydrogel bioscaffoldings and biomedical device coatings |
US8187621B2 (en) | 2005-04-19 | 2012-05-29 | Advanced Cardiovascular Systems, Inc. | Methods and compositions for treating post-myocardial infarction damage |
US8303972B2 (en) | 2005-04-19 | 2012-11-06 | Advanced Cardiovascular Systems, Inc. | Hydrogel bioscaffoldings and biomedical device coatings |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス,インコーポレイティド | ムスカリン性受容体調節による神経発生 |
CA2625153A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US20080058521A1 (en) * | 2006-01-26 | 2008-03-06 | Wyeth | Processes for the preparation of compounds |
TWI401248B (zh) * | 2006-02-15 | 2013-07-11 | Dendreon Corp | Trp-p8活性的小分子調節劑 |
WO2007104035A1 (en) * | 2006-03-08 | 2007-09-13 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
US20100216734A1 (en) * | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US20100009983A1 (en) * | 2006-05-09 | 2010-01-14 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
US9242005B1 (en) | 2006-08-21 | 2016-01-26 | Abbott Cardiovascular Systems Inc. | Pro-healing agent formulation compositions, methods and treatments |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
CA2663347A1 (en) * | 2006-09-19 | 2008-03-27 | Braincells, Inc. | Ppar mediated modulation of neurogenesis |
KR101563010B1 (ko) * | 2006-10-31 | 2015-10-26 | 더 가버먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 리프리젠티드 바이 더 디파트먼트 오브 헬스 앤 휴먼 서비씨즈 | 평활화 폴리펩티드 및 사용 방법 |
WO2008057468A1 (en) * | 2006-11-02 | 2008-05-15 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
WO2008057497A2 (en) * | 2006-11-02 | 2008-05-15 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
WO2008057469A1 (en) * | 2006-11-02 | 2008-05-15 | Wyeth | Small organic molecule regulators of cell proliferation |
US9005672B2 (en) | 2006-11-17 | 2015-04-14 | Abbott Cardiovascular Systems Inc. | Methods of modifying myocardial infarction expansion |
US20080177389A1 (en) * | 2006-12-21 | 2008-07-24 | Rob Gene Parrish | Intervertebral disc spacer |
WO2009042646A1 (en) * | 2007-09-24 | 2009-04-02 | Curis, Inc. | Anti-proliferative agents |
EA201001203A1 (ru) * | 2008-01-29 | 2011-04-29 | Новартис Аг | ПРИМЕНЕНИЕ АГОНИСТОВ Hedgehog ДЛЯ ЛЕЧЕНИЯ СВЯЗАННЫХ С КОСТНО-МЫШЕЧНОЙ СИСТЕМОЙ НАРУШЕНИЙ |
US8969081B2 (en) * | 2008-12-10 | 2015-03-03 | The Trustees Of Columbia University In The City Of New York | Caudal motor neuron derived from embryonic stem cells under conditions essentially free of any retinoid |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
US9677042B2 (en) | 2010-10-08 | 2017-06-13 | Terumo Bct, Inc. | Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
US9708299B2 (en) | 2011-01-03 | 2017-07-18 | Genentech, Inc. | Hedgehog antagonists having zinc binding moieties |
GB201201298D0 (en) | 2012-01-26 | 2012-03-07 | Universitat Leipzig | Therapeutic use of activators of zinc finger protein gli3 |
US9248128B2 (en) | 2012-01-27 | 2016-02-02 | New York University | Method for enhancing remyelination using GLI1 inhibitors |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
JP6466924B2 (ja) | 2013-10-04 | 2019-02-06 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 複素環式化合物及びその使用 |
WO2015073691A1 (en) | 2013-11-14 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating cancer by activation of bmp signaling |
US9617506B2 (en) | 2013-11-16 | 2017-04-11 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
US9775844B2 (en) | 2014-03-19 | 2017-10-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP3613841B1 (en) | 2014-03-25 | 2022-04-20 | Terumo BCT, Inc. | Passive replacement of media |
EP3198006B1 (en) | 2014-09-26 | 2021-03-24 | Terumo BCT, Inc. | Scheduled feed |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
WO2016142427A1 (en) | 2015-03-10 | 2016-09-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method ank kit for reprogramming somatic cells |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
CN105130978B (zh) * | 2015-07-22 | 2017-11-21 | 中国人民解放军军事医学科学院基础医学研究所 | 一种化合物及其在帕金森疾病方面的应用 |
CA2998469A1 (en) | 2015-09-14 | 2017-03-23 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
CN109069426B (zh) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
WO2017106332A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
DK3393468T3 (da) | 2015-12-22 | 2022-12-19 | X4 Pharmaceuticals Inc | Fremgangsmåder til behandling af en immundefektsygdom |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
JP2019510785A (ja) | 2016-04-08 | 2019-04-18 | エックス4 ファーマシューティカルズ, インコーポレイテッド | 癌を処置する方法 |
US11965175B2 (en) | 2016-05-25 | 2024-04-23 | Terumo Bct, Inc. | Cell expansion |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US11332470B2 (en) | 2016-06-21 | 2022-05-17 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
JP7084624B2 (ja) | 2016-06-21 | 2022-06-15 | エックス4 ファーマシューティカルズ, インコーポレイテッド | Cxcr4阻害剤およびその使用 |
ES2870920T3 (es) | 2016-06-21 | 2021-10-28 | X4 Pharmaceuticals Inc | Inhibidores de CXCR4 y usos de los mismos |
SG10201910821XA (en) | 2016-12-30 | 2020-01-30 | Frequency Therapeutics Inc | 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells |
WO2018129470A1 (en) * | 2017-01-09 | 2018-07-12 | The Board Of Trustees Of The Leland Stanford Junior University | Reversing deficient hedgehog signaling restores deficient skeletal regeneration |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
EP3656842A1 (en) | 2017-03-31 | 2020-05-27 | Terumo BCT, Inc. | Cell expansion |
WO2019048898A1 (en) | 2017-09-05 | 2019-03-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION |
US20200397901A1 (en) * | 2018-01-24 | 2020-12-24 | The University Of Tokyo | Photoresponsive smoothened ligand |
US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
WO2020106755A1 (en) | 2018-11-19 | 2020-05-28 | New York University | Inhibitors of gli1 as therapeutic agents |
EP3883932B1 (en) | 2018-11-19 | 2023-03-29 | New York University | Inhibitors of gli1 as therapeutic agents |
CN112898178A (zh) * | 2021-01-25 | 2021-06-04 | 蚌埠产品质量监督检验研究院 | 一种N-Boc-反式-1,4-环己二胺的制备方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3612974A1 (de) * | 1986-04-17 | 1987-10-29 | Basf Ag | 1,4-cyclohexandiamine, verfahren zu ihrer herstellung und ihre verwendung als fungizide |
IL96019A0 (en) * | 1989-10-31 | 1991-07-18 | Fujisawa Pharmaceutical Co | Imidazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same |
JPH0625250A (ja) * | 1992-07-13 | 1994-02-01 | Tooa Eiyoo Kk | チエノ〔3,4−d〕イミダゾール誘導体、その製造法およびそれを含有する循環器官用剤 |
CA2128014A1 (en) * | 1992-12-07 | 1994-06-23 | Toshikazu Shimizu | Process for the preparation of imidazopyridine derivatives and intermediates |
DE4326344A1 (de) * | 1993-08-05 | 1995-02-09 | Thomae Gmbh Dr K | Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US6281332B1 (en) * | 1994-12-02 | 2001-08-28 | The Johns Hopkins University School Of Medicine | Hedgehog-derived polypeptides |
CA2302780A1 (en) * | 1997-08-29 | 1999-03-04 | Ontogeny, Inc. | Regulation of muscle tissues by hedgehog-like polypeptides, and formulations and uses related thereto |
AU753540B2 (en) * | 1998-03-05 | 2002-10-24 | Agouron Pharmaceuticals, Inc. | Non-peptide GnRH agents |
US6291516B1 (en) * | 1999-01-13 | 2001-09-18 | Curis, Inc. | Regulators of the hedgehog pathway, compositions and uses related thereto |
CA2373892A1 (en) * | 1999-05-17 | 2000-11-23 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
AU780846B2 (en) * | 1999-09-16 | 2005-04-21 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
EP1227805B2 (en) * | 1999-10-14 | 2011-02-23 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
DK1272168T3 (da) * | 2000-03-30 | 2006-02-13 | Curis Inc | Sma organiske molekyler som celleproliferationsregulatorer |
-
2001
- 2001-09-26 US US09/964,276 patent/US6683192B2/en not_active Expired - Lifetime
-
2002
- 2002-09-18 JP JP2003530806A patent/JP4563028B2/ja not_active Expired - Lifetime
- 2002-09-18 GE GE5623A patent/GEP20063855B/en unknown
- 2002-09-18 CA CA002461709A patent/CA2461709A1/en not_active Abandoned
- 2002-09-18 EA EA200400355A patent/EA200400355A1/ru unknown
- 2002-09-18 BR BR0212825-0A patent/BR0212825A/pt not_active IP Right Cessation
- 2002-09-18 KR KR1020107018628A patent/KR101051535B1/ko active IP Right Grant
- 2002-09-18 WO PCT/US2002/029522 patent/WO2003027234A2/en active Application Filing
- 2002-09-18 EP EP02773438A patent/EP1436287A4/en not_active Withdrawn
- 2002-09-18 NZ NZ531970A patent/NZ531970A/en unknown
- 2002-09-18 HU HU0402307A patent/HUP0402307A2/hu unknown
- 2002-09-18 PL PL02371343A patent/PL371343A1/xx not_active Application Discontinuation
- 2002-09-18 AU AU2002336580A patent/AU2002336580B2/en not_active Ceased
- 2002-09-18 MX MXPA04002880A patent/MXPA04002880A/es active IP Right Grant
- 2002-09-18 UA UA2004032270A patent/UA78225C2/uk unknown
- 2002-09-18 KR KR1020047004482A patent/KR101039198B1/ko active IP Right Grant
- 2002-09-18 IL IL16110402A patent/IL161104A0/xx unknown
- 2002-09-18 CN CN028233328A patent/CN1578779B/zh not_active Expired - Lifetime
-
2004
- 2004-03-24 ZA ZA200402322A patent/ZA200402322B/xx unknown
- 2004-03-25 NO NO20041260A patent/NO20041260L/no not_active Application Discontinuation
- 2004-03-25 IL IL161104A patent/IL161104A/en active IP Right Grant
-
2013
- 2013-08-25 IL IL228106A patent/IL228106A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL228106A0 (en) | 2013-09-30 |
KR20040045003A (ko) | 2004-05-31 |
PL371343A1 (en) | 2005-06-13 |
WO2003027234A3 (en) | 2003-12-18 |
US20020198236A1 (en) | 2002-12-26 |
WO2003027234A2 (en) | 2003-04-03 |
JP2005520788A (ja) | 2005-07-14 |
CA2461709A1 (en) | 2003-04-03 |
CN1578779A (zh) | 2005-02-09 |
NO20041260L (no) | 2004-05-26 |
US6683192B2 (en) | 2004-01-27 |
WO2003027234A9 (en) | 2004-02-19 |
GEP20063855B (en) | 2006-06-26 |
IL161104A (en) | 2013-08-29 |
CN1578779B (zh) | 2013-09-18 |
KR20100105784A (ko) | 2010-09-29 |
KR101051535B1 (ko) | 2011-07-22 |
BR0212825A (pt) | 2005-05-10 |
NO20041260D0 (no) | 2004-03-25 |
JP4563028B2 (ja) | 2010-10-13 |
UA78225C2 (en) | 2007-03-15 |
KR101039198B1 (ko) | 2011-06-03 |
AU2002336580B2 (en) | 2008-10-30 |
NZ531970A (en) | 2006-11-30 |
EP1436287A4 (en) | 2005-10-26 |
EP1436287A2 (en) | 2004-07-14 |
ZA200402322B (en) | 2005-06-23 |
IL161104A0 (en) | 2004-08-31 |
EA200400355A1 (ru) | 2005-06-30 |
MXPA04002880A (es) | 2005-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0402307A2 (hu) | Kisméretű szerves molekulák a sejtproliferáció szabályozásához és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
DE60218048D1 (de) | Thiophenverbindungen als arzneimittel | |
RU94046169A (ru) | Гетероциклические соединения, способ их получения, способ разделения оптических изомеров, фармкомпозиция, способ лечения | |
NO20040313L (no) | Nye forbindelser | |
NO20053827L (no) | Nye forbindelser. | |
HRP20040317A2 (en) | 1,8-naphthyridine derivatives as antidiabetics | |
DE60111205D1 (de) | Triarylimidazol-derivate als cytokin-inhibitoren | |
HUP0203973A2 (hu) | Szulfonamid-tartalmú heterociklusos vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
BRPI0412851A (pt) | benzamidazóis de n-metila-substituìdos | |
ES2193839A1 (es) | Nuevos derivados de 6-fenildihidropirrolpirimidindiona. | |
DE69827785D1 (de) | 1,4-substituierte cyclische aminderivate | |
NO20054224L (no) | Nye 2-pyridinkarboksamidderivater | |
HUP0002050A2 (hu) | Szubsztituált imidazolvegyületek, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
EA200301306A1 (ru) | Производные 1-фенилсульфонил-1,3-дигидро-2h-индол-2-она, их получение и их терапевтическое применение | |
HUP0402376A2 (hu) | Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények | |
HUP0402191A2 (hu) | Humán metabotrop glutamát receptor antagonista aktivitással rendelkező acetilénszármazékok, eljárás előállításukra, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
DE69903923D1 (de) | Bizyklische pyrrolderivate als mcp-1 inhibitoren | |
HUP0302771A2 (hu) | Nitrozo-difenilamin-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
SE0302116D0 (sv) | Novel compounds | |
BRPI0406500A (pt) | processo farmacêutico e compostos preparados pelo mesmo | |
MY140325A (en) | Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them | |
HUP0200121A2 (hu) | Kalcilitikus vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0303270A2 (hu) | Antidepresszáns hatású izoxazolinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
ATE366248T1 (de) | N-aryl-substituiertes cyclisches aminderivat und medizin, die dieses als wirkstoff enthält | |
ATE337827T1 (de) | N-aryl-4,5-diaminopyrazole und diese verbindungen enthaltende färbemittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |